Q-omics provides the consensus-scored RPS29P12 profile across patient tissues and cancer cell-line models. RPS29P12 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS29P12 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPS29P12 RNA expression shows 6,574 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight LIHC, COAD, and CCRCC as cancer lineages where RPS29P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29P12 survival associations across molecular data types. RPS29P12 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29P12 RNA expression–survival associations across cancer types. High RPS29P12 expression shows unfavorable associations in LIHC, STAD, THCA, THYM and BRCA, but favorable associations in CHOL. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS29P12 RNA expression.
This table summarizes RPS29P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS29P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29P12 shows lower tumor expression in COAD, LUSC and READ and higher tumor expression in PAAD and UCEC. The COAD box plot shows higher RPS29P12 RNA expression in normal versus tumor tissue (log2 FC = −0.868, t-test p < 0.001).
This table shows molecular features associated with RPS29P12 in patient tissues and cancer cell lines. In patient samples, RPS29P12 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
